Seattle Genetics Inc (SGEN)

66.70
NASDAQ : Health Care
Prev Close 66.71
Day Low/High 66.27 / 67.87
52 Wk Low/High 26.02 / 75.36
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 141.55M
Market Cap 9.44B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Presents Data From Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Diffuse Large B-cell Lymphoma At ASH Annual Meeting

Seattle Genetics Presents Data From Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Diffuse Large B-cell Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) combination therapy in frontline diffuse large...

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 5, 2016 during the 58th American Society of Hematology (ASH) Annual Meeting in San Diego,...

Seattle Genetics Receives FDA Breakthrough Therapy Designation For ADCETRIS® (Brentuximab Vedotin) In Mycosis Fungoides And Primary Cutaneous Anaplastic Large Cell Lymphoma

Seattle Genetics Receives FDA Breakthrough Therapy Designation For ADCETRIS® (Brentuximab Vedotin) In Mycosis Fungoides And Primary Cutaneous Anaplastic Large Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that the U.

Seattle Genetics And Takeda Complete Enrollment Of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Mature T-cell Lymphoma

Seattle Genetics And Takeda Complete Enrollment Of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Mature T-cell Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced completion of patient enrollment in the ECHELON-2 clinical trial.

Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company's Expanding Global Leadership In The Development Of Innovative Antibody-Drug Conjugates

Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company's Expanding Global Leadership In The Development Of Innovative Antibody-Drug Conjugates

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 18 abstracts including eight oral presentations have been accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting and...

Seattle Genetics To Present At Credit Suisse 25th Annual Healthcare Conference

Seattle Genetics To Present At Credit Suisse 25th Annual Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that  Clay Siegall, Ph.

Seattle Genetics Reports Third Quarter 2016 Financial Results

Seattle Genetics Reports Third Quarter 2016 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2016.

Seattle Genetics Demonstrates Commitment To Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations At ISHL 2016

Seattle Genetics Demonstrates Commitment To Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations At ISHL 2016

Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple data presentations at the 10 th International Symposium on Hodgkin Lymphoma (ISHL) taking place in Cologne, Germany, October 22-25, 2016, evaluating...

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.

Seattle Genetics And Agensys, An Affiliate Of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress

Seattle Genetics And Agensys, An Affiliate Of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress

Seattle Genetics, Inc. (NASDAQ: SGEN) and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO)...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Third Quarter 2016 Financial Results On October 27, 2016

Seattle Genetics To Host Conference Call And Webcast Discussion Of Third Quarter 2016 Financial Results On October 27, 2016

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2016 financial results on Thursday, October 27 after the close of financial markets.

Seattle Genetics Announces Executive Promotions And Leadership Appointment

Seattle Genetics Announces Executive Promotions And Leadership Appointment

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced two executive promotions and an executive appointment to the company's clinical development leadership team.

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD123A For Patients With Relapsed Or Refractory Acute Myeloid Leukemia

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD123A For Patients With Relapsed Or Refractory Acute Myeloid Leukemia

Seattle Genetics, Inc. (NASDAQ: SGEN) today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD123A for patients with relapsed or refractory acute myeloid leukemia (AML).

Analysts' Actions -- Cognizant, Dick's, Seattle Genetics, VF Corp. and More

Analysts' Actions -- Cognizant, Dick's, Seattle Genetics, VF Corp. and More

Here are Thursday's top research calls, including upgrades for Dick's Sporting Goods and Seattle Genetics, and downgrades for Cognizant and VF Corp.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are scooping up shares of their own stock lately.

Seattle Genetics To Present At Morgan Stanley Global Healthcare Conference

Seattle Genetics To Present At Morgan Stanley Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.

Http://www.seattlegenetics.com/

Http://www.seattlegenetics.com/

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc.

Barbarian At The Gate: Seattle Genetics (SGEN)

Barbarian At The Gate: Seattle Genetics (SGEN)

Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Analysts' Actions -- Alaska Air, Southwest, Coach, Twitter and More

Analysts' Actions -- Alaska Air, Southwest, Coach, Twitter and More

Here are Wednesday's top research calls, including upgrades for Coach and Alaska Air, and downgrades for Southwest Airlines and Twitter.

Seattle Genetics Reports Second Quarter 2016 Financial Results

Seattle Genetics Reports Second Quarter 2016 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the second quarter ended June 30, 2016.

Seattle Genetics And Takeda Announce Publication Of Final Data From ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood

Seattle Genetics And Takeda Announce Publication Of Final Data From ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood

Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS (brentuximab vedotin) monotherapy pivotal Phase 2 clinical trial in relapsed...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter 2016 Financial Results On July 26, 2016

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter 2016 Financial Results On July 26, 2016

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets.

Seattle Genetics Announces European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) As Consolidation Treatment In Post-Transplant Hodgkin Lymphoma

Seattle Genetics Announces European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) As Consolidation Treatment In Post-Transplant Hodgkin Lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its collaborator Takeda Pharmaceutical Company, Limited, received marketing authorization by the European Commission for ADCETRIS (brentuximab vedotin) for the...

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

5 Best-Positioned Biotech Stocks on Brexit Volatility

5 Best-Positioned Biotech Stocks on Brexit Volatility

Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of The European Hematology Association

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of The European Hematology Association

-Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 76 Percent Objective Response Rate, Including a 41 Percent Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 33A Combination Therapy-

Insider Trading Alert - ELGX, SGEN And JYNT Traded By Insiders

Insider Trading Alert - ELGX, SGEN And JYNT Traded By Insiders

Stocks with insider trader activity include ELGX, SGEN and JYNT